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Studies on Protein Inhibitors of the Extension of 
Alzhiemer's Fibrils (AP1-40) using a Sensitive 
Streptavidin-Europium Assay 
Alan J. Greene Jr. 
Mentor and P.I. : Dr. Ronald Wetzel Ph.D 
Department of Biochemistry and Cellular and Molecular Biology 
University of Tenneesse, Knoxville, TN, 37920 
Abstract: 
Amyloid plaques, comprised mainly of a fibrillar form of amyloid ~ protein (A~), 
are a defining pathological feature of Alzheimer' s disease (AD). Therefore, studies on 
Alzheimer's disease have concentrated on obtaining potent protein and peptide inhibitors 
of A~ fibrillogeneses . We have explored the inhibitory activities of BSA, HSA, and 
ovarian ovalbumin on the rate of fibril extension in-vitro using a very sensitive microplate 
assay. In contrast to other extension assays that use high concentrations of A~ (/lM 
range) we can measure the extension of fibrils down to the sub-fmol range using 
physiological concentrations of A~ (nM range) . Sonicating A~ fibrils greatly increases the 
fibril ' s ability to seed the extension reaction. This enhancement of seeding ability is most 
likely due to an increase in the number of fibril growing ends that are accessible to A~ 
monomer binding. 
All the proteins in our inhibition studies, even the ovarian ovalbumin, have similar 
inhibitory potencies. For example, similar concentrations of the inhibitors (2J.1.M) inhibit 
the rate of fibril extension by 25-30%. This suggests that many polypeptides are be able 
to inhibit fibril extension. To test whether the proteins require a native folded structure to 
inhibit fibril extension, the inhibitors were denatured by breaking their disulfide bonds 
using reduction and alkylation. Surprisingly, we found that these modifications enhanced 
their inhibitory potencies by 2 fold in most cases. An ICso value of 0.18/lM was 
determined for modified HSA. These results suggest that the protein' s native structure 
plays little to no role in the inhibition of fibril extension. 
Introduction: 
Alzheimer's disease (AD) is a progressive senile dementia'that effects a 
significant amount of the elderly [1], Amyloid plaques, hard waxy deposits 
consisting of proteins and polysaccharide, are the defining pathological feature 
of the AD brain [2]. The major constituent of amyloid is a hydrophobic 30-43 
amino acid peptide, p-amyloid (AP) [3]. AP is a cleavage product of a large 
trans-membrane protein, amyloid precursor protein, that is encoded by the APP 
gene [4] . 
Similar concentrations of AI3 (nM) have been observed in the plasma and 
cerebral spinal fluid (CSF) of both normal and AD patients [5]. Also, AI3 is 
constitutively produced by cells in culture [6]. However, several studies show 
that the accumulation of insoluble rather than soluble AP is linked to AD. For 
example, the transition of AI3 from soluble to insoluble peptide is associated with 
the onset of cellular toxicity [4]. In addition, overproduction of the peptide in 
transgenic mice leads to both Significant AP deposition and neuronal toxicity [7]. 
Therefore, the suppression or prevention of the transition of AP from monomeric 
to a toxic insoluble aggregate has emerged as a goal in the development of 
therapy for AD [3]. 
The majority of assays that are currently used to measure the inhibition of 
fibril growth by inhibitors suffers a major drawback. These assays require high 
concentrations of AI3 (in the 11M range) that are significantly .greater than the 
physiological concentration of AI3 (in the nM range) [5]. One assay uses 
physiological concentrations of AI3 , but it also uses radio-labeled AI3 [8] . In 
contrast, we have studied the inhibitory potencies of native and denatured BSA, 
HSA, and Dvalbumin using a sensitive microplate assay that uses physiological 
concentrations of biotinylated Ap. The rate of fibril extension is monitored by 
measuring time-resolved fluorescence of europium. The europium probe is 
attached to biotinylated AP using streptavidin. This method eliminates the 
damaging ionizing radiation associated with radio-labeled Ap. 
Using the microplate assay we screened several proteins for any 
inhibitory activity on AP fibril extension. All of the proteins tested have similar 
inhibitory potencies. To determine if the proteins require a native folded 
structure to inhibit fibril extension the inhibitory proteins were modified by 
reduction and alkylation. We found that these modifications enhances the 
inhibitory potency of the proteins. The results suggest that the native structure 
of the protein plays little to no role in the protein's inhibitory activity of fibril 
extension. 
Methods and Materials: 
Materials: A~ fibrils and biotinylated A~ were prepared by others using 
unconjuqated and cysteine (N-terminal) conjugated A~ peptides obtained from 
Quality Controlled Biochemicals (Hopkinton, MA). Essentially fat free bovine 
serum albumin (BSA), human serum albumin (HSA), and ovarian ovalbumin 
were obtained from sigma. All chemicals were of analytical grade. 
Preparation of sonicated fibrils and coating of the micro titer plate: To A~ 
fibrils (a gift from B. O'Nualiian; UT Medical Center, Knoxville TN) in phosphate 
buffered saline (PBS) and O.OS% sodium azide, at pH 7.4 (standard buffer) , a 
solution of 1mM dithiothreiroJ and O.SmM EDTA was added. The fibril solution 
was sonicated on ice for 0-2S0 seconds (30s burst) using a Tekmar sonicator. 
Aliquots (1 OOIlL) of 0.2Sllg/mL A~ fibrils in standard buffer were pi petted into the 
wells of a high binding microtiter plate (Corning EINRIA plate) . Control wells 
were not coated with fibrils . The plate was then sealed, and allowed to incubate 
at room temperature for 2.S days. After incubation the plate was washed twice 
with a wash buffer (PBS and 0.01 % tween). Wells of the micr.otiter plate were 
blocked with 200llL of PBS containing 0.3% gelatin, sealed and incubated for 2 
hours at 37°C. The plate was then washed with washing buffer, and 1 OOIlL of 
standard solution was placed in each wel l. The plate was seated, and stored for 
up to two weeks at 4°C (Figure 1). 
Extension Assay: AJiquots (100IlL) of SnM biotinylated A~ monomer (a 
gift from R. Wetzel UT Medical Center, Knoxville, TN) in standard buffer with or 
without inhibitor present (0.2-30IlM) was added to specific control and sample 
wells of the microplate over a period of 6h at 37°C (Figure 1). Experimental 
data was measured in triplicate. After the final time point, the plate was washed 
twice and 100llL of O.1llg/ml strepavidin-europium complex (Wallac corp.) was 
added to each well. The plate was sealed and incubated for 1 h at room 
temperature. After 1 hour the plate was washed three times and 100llL of 
enhancement solution (Wallac corp.) was added to each well for 5-7min, at room 
temperature (Figure 1). Time resolved Europium fluorescence was measured 
using a Wallac 1420 Victo~ Multilabel Counter. The rates of extension were 
then calculated by plotting the amount of AI3 that deposited onto the fibril seed 
(corrected using control readings) and obtaining the initial rate of the extension 
reaction directly from the slope of the straight line that best fits the data. 
Fluorimetry: Protein and ANS fluorescence were monitored at room 
temperature using a Perkins Elmer Luminescence Spectrometer LS50B. 
Readings were carried out using 11lM protein in PBS, with or without 21lM ANS, 
pH 7.4. The protein and ANS fluorescence were measured with excitation at 
280nm and 350nm respectively. The emission and excitation slits were both set 
at 5nm for protein fluorescence measurements. Slits of 2.5nm and 5nm were 
used when measuring ANS fluorescence. 
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Figure 1. Schematic Representation of the Af3 Fibril Extension Microplate 
Assay. Step 1: The microplate is coated with sonicated synthetic fibrils then bl()(;ked 
with gelatin. Step 2: A biotinylated A~ monome-r solution is added and aJIowed in 
incubate with or without inhibitor at intervals for up to 6 h. Step 3: The Strepavidin-
Europium complex is added to the plate and allowed to incubate at room temperature 
for 1 hour. Between each step the wells were washed. For a more detailed 
explanation of the experiment see Methods and Materials . 
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Figure 2. Determination of the Initial Rate of Af3 Fibril Extension. The reaction was 
monitored using the microplate assay with each well containing 25ngllOOl-tL of sonicated fibrils 
and 5nM biotinylated A~ monomer with no inhibitor present at 37°C for 0-6 hours as is described 
in the Methods and Materials. 
0.25 
-.c . 
- 0.2 '0 §. 
c 0.15 0 
'';:; 
c 
Q) 
- 0.1 >< w 
.... 
0 
2 0.05 co 
0::: 
a 
0 50 100 150 200 250 
Sonication Time (s) 
Figure 3. Effect of Sonication on Initial Fibril Extension. The reaction was monitored using 
the microplate assay with each well 25ngllOO!JL of fibrils and 5nM biotinylated AP monomer at 37Co 
for 0-6 hours. 
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Figure 4. The Effects of Modified HSA on the Rate of Af3 Fibril Extension. The reaction 
was monitored at 37Co as is described in Figure 3 and as described in the Methods and Materials. 
Table I Comparison of the Intrinsic and Extrinsic Fluorescence Properties 
of Native and Modified Protein Inhibitors of A~ Fibril Extension. Protein and 
ANS fluorescence wavelength scans were carried out with excitation at 280nm and 396nm respectively. 
The excitation and emission slits used were 5nm and lOnm respectively. Each fluorescence reading was 
. d . hIM f . . d 'bed ' M 1 ds dM . 1 carne out WIt !.I. o . protem at room temperature as IS escn m et 10 an atena s. 
Protein Protein Fluorescence ANS Fluorescence 
/, max Yield /, max Yield 
(nm) (arbitrary units) (nm) (arbitrary units) 
BSA 347 715 475 475 
Modified BSA 334 704 475 280 
Ovalbumin 337 377 482 74 
Modified Ovalbumin 337 . 628 474 278 
HSA 341 153 476 270 
Modified HSA 324 155 476 193 
Table II Comparison of the Abilities of Native and Modified Proteins to 
Inhibit the Rate of AJ3 Fibril Extension. The percentages of inhibition were detennined by 
comparing the initial rate of fibril extension with and without an inhibitor present for example Figures I 
and 4. The initial rate offibril extension was monitored using the microplate assay as is described in 
Methods and Materials. 
Inhibitor Protein Inhibition 
(%) 
BSA 26.8 
Modified BSA 51.3 
Ovalbumin 30.1 
Modified Ovalbumin 38.8 
HSA 25.9 
Modified HSA 40.7 
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Figure 5. Determination of the ICso Value for the Inhibition of the Rate of AI3 Fibril Extension 
by Modified HSA. The percentage inhibition of the reaction by modified HSA was calculated using 
values for the il1itial rate of the reaction as is described in Figures 1,4 and Methods and Materials. 
All le50 ofO . 18~ was determined for Modified HSA. 
Results: 
The time resolved fluorescence microplate assay that was used to 
monitor the extension of AP fibrils is very sensitive. This sensitivity is because of 
the high fluorescence of the probe (Europium) and because the fluorescence of 
the probe is measured after a brief waiting period that allows the background 
fluorescence to decay and therefore be reduced. In contrast, the use of real 
time fluorescence to monitor the reaction can often be limited by background 
noise. Using the microplate assay, we can measure the deposition of AJ3 onto 
A13 fibrils down to the sub fmol range (Figure 2). The initial rate of fibril 
extension (0.3047 fmol h-1) with physiolgical concentrations (nM) of AJ3 [5] is 
reproducibly linear up to six hours (Figure 2). The signal for the deposition of 
A13 monomer at onto fibrils at a sub fmol range is consistently at least 3 fold 
greater than the signal obtained for control wells that contain no fibril seed (data 
not shown). 
The sonication of AP fibrils is known to increase the potency as a seed in 
fibril extension reactions [9]. Therefore, as expected sonication of the A13 fibrils 
up to the sonication time (150 s) that we use as our standard condition in our 
assay increased the rate of the extension reaction (Figure 3). In contrast, 
sonication for greater than 150 seconds causes the rate of the reaction to 
decrease by about 20%. Interestingly, no rate of fibril extension was monitored 
when the fibrils were unsonicated (Figure 3). 
The extension assay is a potentially powerful tool to screen the abilities of 
protein to inhibit fibril extension at physiological concentrations of A13· 
Therefore, we have screened the abilities of proteins that are known to inhibit 
fibril formation (BSA,HSA) and a protein, ovarian ovalbumin, that is not known to 
inhibit the reaction. All of the proteins even the ovarian ovalbumin similarly 
inhibited the rate of fibril extension (Figures 4&5; Table I). The effects of 
denaturing (modifying) the inhibitors ,by breaking their disulfide bridges, on their 
activities was tested using their reduced and alkylated forms ( A gift from B. 
Q'Nualiain; UT Medical Center, Knoxville TN). Surprisingly, modification of the 
proteins improves their inhibitory abilities (Figure 4; Table I). For example there 
are 2 fold and 3.5 fold decrease in the rate of fibril extension in the prescence of 
0 .2~M and 30~M modified HSA (Figure 4). 
To confirm the modification of the protein inhibitors their intrinsic and 
extrinsic fluorescence properties were measured. Modification of the proteins 
significantly affects intrinsic and extrinsic fluorescent properties (Table II). For 
protein fluorescence, modification of the albumins results in a blue shift of their 
maximum wavelength emissions by 13-17nm respectively (Table I). ANS 
fluorescence is used for studying the hydrophobic binding sites on the proteins 
[10,11]. The ANS fluorescence yield for modified albumins is about half that of 
the native proteins (Table II). Modification of ovalbumjn results in about a 2 fold 
and 4 fold increases in protein and ANS fluorescence respectively (Table II). 
An IC50 value is defined as the concentration of inhibitor that gives 50% of 
its total inhibition potency. An IC50 value of 0 . 18~M was determined for the 
inhibitory activity of modified HSA (Figure 5). None of the proteins tested, either 
in the native or the modified forms were able to inhibit fibril extension 100%. 
Discussion: 
The microplate extension assay (developed by R. Wetzel ; UT Medical 
Center, Knoxville, TN) that was used to screen protein inhibitors is a very 
sensitive assay that cam measure fibril extension down to the sub-fmollevel with 
minimum background noise. This microplate assay is based on an fibril 
extension assay [81 that uses radio-labeled Af3 which requires considerable care, 
and is unstable, producing damaging ionizing radiation . In contrast, our assay 
uses biotinylated Af3 which is not toxic and relatively cheap. The results of our 
studies show that the extension assay is amenable to high-throughput screening 
for the identification of Af3 deposition inhibitors using physiological 
concentrations of Af3. 
The enhanced seed potencies of sonicated fibrils relative to unsonicated 
has previously been described by Jarrett and Landsbury [9]. Sonication of fibrils 
is likely to increase the available growing ends for the deposition of Af3 
monomer. In contrast, the decline in the fibrils abil ity to undergo extension after 
150s is interesting. This reduction in seed potency by repeated sonication is 
evidently because of effects on the higher order structure of the fibril. In this 
regard, studies in our lab (B. O'Nualiian) confirm that sonication of fibrils for long 
periods results in a reduction in their abi lities to interact with Thioflavin-T, a 
fluorescent die that bind specifically to amyloid. 
The inhibitory activities of all the proteins tested suggest that many 
polypeptides can inhibit fibril extension. Yet the mechanism of inhibition remains 
unknown. However, information can be drawn from the protein screenings. 
Proteins exist in both native and non-native states. All of the native proteins 
screened have inhibitory activity. However, in all cases there was an increase in 
inhibitory potency with the modification of the proteins, where there are no native 
structures present. One hypothesis is that the three dimensional structure of the 
native protein plays little to no role in the inhibition of fibril extension. Future 
studies could concentrate on the inhibitory mechanism of the modified proteins. 
Conditions that favor the non-native states of the inhibitors such as denaturants 
and temperature could be used to investigate our hypothesis. 
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